A new subtype of lymphoma:Double-hit lymphoma with bcl-2 and myc translocation

Hui lai Zhang, Qin Ma, Kai Fu, Hua qing Wang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Double-hit lymphoma (DHL) is a kind of disease with features intermediated between diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL), usually accompanied by myc gene breakpoint with other recurrent chromosomal breakpoint and mainly involving myc and bcl-2 translocation. The presentation of this disease is characterized by elevated serum lactate dehydrogenase levels, B symptoms, bone marrow involvement, advanced stage disease, extranodal involvement, and central nervous system involvement. Because its features are similar with DLBCL and BL, it's difficult to distinguish them by pathological diagnosis. At present, the differential diagnosis is mainly by chromosomal analysis (G-banding), FISH and immunohistochemistry. This subtype received a poor response to conventional chemotherapy for DLBCL, and has a poor prognosis. The median survival time is only 0.2-1.5 years. Currently, the main regimens include RCHOP, RICE, RCVD, methotrexate prophylaxis for central nervous system involvement, high-dose chemotherapy and bone marrow transplantation.

Original languageEnglish (US)
Pages (from-to)712-715
Number of pages4
JournalJournal of Leukemia and Lymphoma
Volume21
Issue number12
DOIs
StatePublished - Dec 1 2012

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Lymphoma
Burkitt Lymphoma
Central Nervous System
Drug Therapy
myc Genes
Bone Marrow Transplantation
Methotrexate
Differential Diagnosis
Bone Marrow
Immunohistochemistry
Serum

Keywords

  • Double-hit lymphoma
  • Genes, bcl-2
  • Genes, myc

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

A new subtype of lymphoma:Double-hit lymphoma with bcl-2 and myc translocation. / Zhang, Hui lai; Ma, Qin; Fu, Kai; Wang, Hua qing.

In: Journal of Leukemia and Lymphoma, Vol. 21, No. 12, 01.12.2012, p. 712-715.

Research output: Contribution to journalArticle

Zhang, Hui lai ; Ma, Qin ; Fu, Kai ; Wang, Hua qing. / A new subtype of lymphoma:Double-hit lymphoma with bcl-2 and myc translocation. In: Journal of Leukemia and Lymphoma. 2012 ; Vol. 21, No. 12. pp. 712-715.
@article{6a318685aa76413c998ec14c9bdfdc28,
title = "A new subtype of lymphoma:Double-hit lymphoma with bcl-2 and myc translocation",
abstract = "Double-hit lymphoma (DHL) is a kind of disease with features intermediated between diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL), usually accompanied by myc gene breakpoint with other recurrent chromosomal breakpoint and mainly involving myc and bcl-2 translocation. The presentation of this disease is characterized by elevated serum lactate dehydrogenase levels, B symptoms, bone marrow involvement, advanced stage disease, extranodal involvement, and central nervous system involvement. Because its features are similar with DLBCL and BL, it's difficult to distinguish them by pathological diagnosis. At present, the differential diagnosis is mainly by chromosomal analysis (G-banding), FISH and immunohistochemistry. This subtype received a poor response to conventional chemotherapy for DLBCL, and has a poor prognosis. The median survival time is only 0.2-1.5 years. Currently, the main regimens include RCHOP, RICE, RCVD, methotrexate prophylaxis for central nervous system involvement, high-dose chemotherapy and bone marrow transplantation.",
keywords = "Double-hit lymphoma, Genes, bcl-2, Genes, myc",
author = "Zhang, {Hui lai} and Qin Ma and Kai Fu and Wang, {Hua qing}",
year = "2012",
month = "12",
day = "1",
doi = "10.3760/cma.j.issn.l009-9921.2012.12.004",
language = "English (US)",
volume = "21",
pages = "712--715",
journal = "Journal of Leukemia and Lymphoma",
issn = "1009-9921",
publisher = "Editorial Board of Journal of Leukemia and Lymphoma",
number = "12",

}

TY - JOUR

T1 - A new subtype of lymphoma:Double-hit lymphoma with bcl-2 and myc translocation

AU - Zhang, Hui lai

AU - Ma, Qin

AU - Fu, Kai

AU - Wang, Hua qing

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Double-hit lymphoma (DHL) is a kind of disease with features intermediated between diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL), usually accompanied by myc gene breakpoint with other recurrent chromosomal breakpoint and mainly involving myc and bcl-2 translocation. The presentation of this disease is characterized by elevated serum lactate dehydrogenase levels, B symptoms, bone marrow involvement, advanced stage disease, extranodal involvement, and central nervous system involvement. Because its features are similar with DLBCL and BL, it's difficult to distinguish them by pathological diagnosis. At present, the differential diagnosis is mainly by chromosomal analysis (G-banding), FISH and immunohistochemistry. This subtype received a poor response to conventional chemotherapy for DLBCL, and has a poor prognosis. The median survival time is only 0.2-1.5 years. Currently, the main regimens include RCHOP, RICE, RCVD, methotrexate prophylaxis for central nervous system involvement, high-dose chemotherapy and bone marrow transplantation.

AB - Double-hit lymphoma (DHL) is a kind of disease with features intermediated between diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL), usually accompanied by myc gene breakpoint with other recurrent chromosomal breakpoint and mainly involving myc and bcl-2 translocation. The presentation of this disease is characterized by elevated serum lactate dehydrogenase levels, B symptoms, bone marrow involvement, advanced stage disease, extranodal involvement, and central nervous system involvement. Because its features are similar with DLBCL and BL, it's difficult to distinguish them by pathological diagnosis. At present, the differential diagnosis is mainly by chromosomal analysis (G-banding), FISH and immunohistochemistry. This subtype received a poor response to conventional chemotherapy for DLBCL, and has a poor prognosis. The median survival time is only 0.2-1.5 years. Currently, the main regimens include RCHOP, RICE, RCVD, methotrexate prophylaxis for central nervous system involvement, high-dose chemotherapy and bone marrow transplantation.

KW - Double-hit lymphoma

KW - Genes, bcl-2

KW - Genes, myc

UR - http://www.scopus.com/inward/record.url?scp=84880739433&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880739433&partnerID=8YFLogxK

U2 - 10.3760/cma.j.issn.l009-9921.2012.12.004

DO - 10.3760/cma.j.issn.l009-9921.2012.12.004

M3 - Article

VL - 21

SP - 712

EP - 715

JO - Journal of Leukemia and Lymphoma

JF - Journal of Leukemia and Lymphoma

SN - 1009-9921

IS - 12

ER -